Trial Profile
A SINGLE CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE BIOEQUIVALENCE OF AN ORAL MERCAPTOPURINE SUSPENSION 100 mg / 5 mL VERSUS AN ORAL MERCAPTOPURINE TABLET 50 mg (PURINETHOL) IN AT LEAST 62 HEALTHY MALE SUBJECTS UNDER FASTING CONDITIONS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mercaptopurine (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- 15 Oct 2012 New trial record